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Open access undNew evidence based regimens and novel high precision technology have reinforced the important role of
radiotherapy in the management of cancer. Current data estimate that more than 50% of all cancer
patients would beneﬁt from radiotherapy during the course of their disease. Within recent years, the
radiotherapy community has become more than conscious of the ever-increasing necessity to come up
with objective data to endorse the crucial role and position of radiation therapy within the rapidly chang-
ing global oncology landscape. In an era of ever expanding health care costs, proven safety and effective-
ness is not sufﬁcient anymore to obtain funding, objective data about cost and cost-effectiveness are
nowadays additionally requested.
It is in this context that ESTRO is launching the HERO-project (Health Economics in Radiation Oncol-
ogy), with the overall aim to develop a knowledge base and a model for health economic evaluation of
radiation treatments at the European level. To accomplish these objectives, the HERO project will address
needs, accessibility, cost and cost-effectiveness of radiotherapy. The results will raise the proﬁle of radio-
therapy in the European cancer management context and help countries prioritizing radiotherapy as a
highly cost-effective treatment strategy.
This article describes the different steps and aims within the HERO-project, starting from evidence on
the role of radiotherapy within the global oncology landscape and highlighting weaknesses that may
undermine this position.
 2012 Elsevier Ireland Ltd.Open access under CC BY-NC-ND license.Radiotherapy and Oncology 103 (2012) 109–112With an estimated 3.2 million new cases and responsible for 1.7
million deaths each year (or one-fourth of the overall mortality),
cancer is a major health care problem in Europe [1]. And will re-
main so: due to the aging of the European population and the
strong association between cancer risk and age, a further increase
in cancer burden – in terms of incidence as well as mortality – is to
be expected. Fortunately, the most recent EUROCARE project re-
ported improved age-speciﬁc cancer survival over time, suggesting
that the wide-spread efforts in early detection and improved can-
cer treatment – not in the least related to more optimized radio-
therapy – pay off. Conversely, even if differences in cancer
survival within and between countries are diminishing, substantial
variation persists, which is at least in part related to differences in
effectiveness of diagnosis and treatment. Knowledge on survival
patterns and comparison among regions and countries stimulate
the analysis of shortcomings in the current situation and the devel-
opment and/or improvement of cancer treatment plans [2,3].
The impact of radiotherapy in cancer survival, alone or in
conjunction with other treatments, has been estimated at 40%,
compared to 49% of patients being cured by surgery and 11% bylogy Department, University
m.
ievens).
er CC BY-NC-ND license.systemic treatments [4]. Innovative radiotherapy technologies,
such as intensity-modulated, image-guided and stereotactic radio-
therapy, introduced in daily practice for many indications after
intensive investigation [5–13], have further endorsed the impor-
tant role of radiotherapy in the radical and palliative treatment
of cancer.
Delaney et al. deﬁned the access rate for radiotherapy as the
proportion of cancer patients receiving appropriate radiotherapy
at least once during the treatment of their malignancy. Based on
detailed modeling, they deﬁned radiotherapy to be a necessary
component of treatment in approximately 52% of all newly diag-
nosed cancers [14]. Derived for the Australian population and evi-
dence-based guidelines in early 2000, this ﬁgure has been accepted
to apply more generally for developed countries and has been used
as a reference for benchmarking the actual radiotherapy utilization
in different countries. In the UK, for example, highly variable access
rates for radiotherapy, ranging between 25% and 49%, have been
observed [15]. Although it has been recognized that prevailing
differences in cancer incidence and palliative/curative patient
mix may translate into utilization levels for radiotherapy that
diverge from the above stated number of 52% [16], such consider-
ations should not play a major role in the context of countries such
as the UK. Hence the necessity to look for other reasons to explain
this ﬁnding.
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Firstly, it can be questioned to what extent clinicians (are will-
ing to) adhere to clinical guidelines, of which a successful imple-
mentation is expected to improve quality of care by decreasing
inappropriate variation and promoting the utilization of effective
therapeutic advances into everyday practice [17].
Unfortunately, patterns of care studies seem to demonstrate
that neither widespread availability of level I literature evidence,
nor existing guidelines, are sufﬁcient preconditions to homogenize
patient care in radiotherapy. One striking example is the treatment
of uncomplicated metastatic bone pain, where multiple random-
ized trials have proven the equivalence – in terms of pain control
and survival – of single fractions compared to fractionated radio-
therapy regimens. Regardless, analyses performed in different
parts of the world have all observed a large variation in practice,
with an overall predominance of fractionated regimes [18–20].
Similarly, the development of guidelines for (3D conformal) radio-
therapy in lung cancer does not seem to have translated yet into a
consistent approach for locally-advanced non-small cell lung can-
cer [21,22].
Many factors have been described to explain physician’s reluc-
tance to implement changing evidence in their practice [17,23].
The use of different radiotherapy schemes may in part be ex-
plained by clinical arguments, such as the age and perceived prog-
nosis of the individual patient. Moreover, personal characteristics
of the physician, dealing with clinical uncertainty and perceived
risk, and the prevailing opinion, with an inclination to adhere to
departmental policy and past teaching, may play a role as well.
In addition, socio-economic factors are known to affect treat-
ment chosen and delivered. Whereas the lack of resources typically
stimulates the use of fewer, less complex, less costly and poten-
tially less qualitative treatments, the opposite observation – i.e.
the more frequent use of high-tech, costly and potentially inappro-
priate treatments – is found if resources are plentiful. The analysis
on radiotherapy dose fractionation, access and waiting times in dif-
ferent UK countries, for example, correlated lower radiotherapy
utilization to the limited availability of radiotherapy staff and ser-
vices in the different regions [24]. Similarly, the patterns of care
studies on lung cancer radiotherapy in Spain and in eastern and
central European countries both suggested that variation in prac-
tice may decrease with proper public health-care planning of re-
sources [21,22]. Hence the necessity to optimize radiotherapy
accessibility and to adapt, as much as reasonably achievable, the
provision of radiotherapy facilities to the estimated needs of the
individual countries and regions.
Once the stafﬁng and infrastructure requirements have been
identiﬁed, actions should be taken to overcome the potentially un-
met needs. As it may take many years to accomplish, a ﬁrst impor-
tant action is to stimulate training programs for the formation of
skilled personnel. Besides, the shortage in terms of infrastructure,
equipment as well as the actual number of radiotherapy depart-
ments should be overcome. Obviously, this may be equally time
consuming and moreover highly dependent of the ﬁnancial deter-
minants of the region or country. A relationship between the num-
ber and type of equipment and the gross income of the country has
been described in different parts of Europe [22,25].
Last but not least, it should be recognized that money does not
only drive practice at the macro level – i.e. through capital invest-
ment on a national basis – but that it is a powerful incentive at the
micro level of medical decision-making as well [26]. Physicians
tend to adapt their clinical behavior to the reimbursement offered,
more or less independently from the available resources [27]. The
different practice surveys on bone metastases indeed suggested
that the antalgic radiotherapy schedules in vogue in differentcountries were closely linked with the prevailing reimbursement
system: protracted schedules when fee-for-service dominates
reimbursement compared to hypofractionation and single frac-
tions in budget and/or case payment systems [19,28].
These observations highlight the complex interplay between
the different factors that may inﬂuence optimal radiotherapy utili-
zation and delivery, as well at the level of the patient–physician
interaction, as from a more general, societal perspective.
Radiotherapy stafﬁng and infrastructure
The ﬁrst real attempt to arrive at estimates for the appropriate
level of radiotherapy infrastructure and stafﬁng in Europe was per-
formed by the QUARTS-project (Radiation Therapy for Cancer:
QUAniﬁcation of RadioTherapy Infrastructure and Stafﬁng Needs).
This project, supported by a European Union (EU) grant, had the
primary aim to provide health care planners and policy makers
with objective data regarding radiotherapy requirements, by com-
bining epidemiology data and evidence-based radiotherapy indica-
tions with information about resource availability [25,29]. Results
were analyzed in function of the gross domestic product (GDP) per
capita: countries with GDP/capitaP US$10.000 were deﬁned as
high resource countries, while medium and low resource countries
as those having a GDP/capita between US$3.000–US$10.000 and
lower than US$3.000, respectively. As a ﬁrst step, guidelines for
the number of equipment and/or personnel were questioned in
all 44 European countries [29]. Guidelines were available in 17
countries (41.5% of the responders). Whereas there was a wide
range in recommended personnel (one radiation oncologist per
150–400 patients treated annually; mean 250), this was not re-
lated to the type of countries. In contrast, the recommendations
for the equipment (number of accelerators, linacs as well as Cobalt
machines) required per number of inhabitants was determined by
national income (i.e. an average of 1/183.000, 1/284.000 and
1/500.000 in res. high, medium and low resource countries). As
personnel costs are most frequently in line with the average
income in a country, they may not have a major impact on the
number of professionals. The price of machines, however, is more
independent of national prosperity. High equipment costs may
therefore obstruct optimal expansion of the infrastructure in
low-income countries, further translating in more restrictive
guidelines. Based on the existing guidelines it was suggested that
one radiation oncologist should be available per 200–250 patients
annually and that one linear accelerator should serve 450 patients.
But obviously, such crude guidelines may not be adequate for wide
application in different (European) countries, all being character-
ized by speciﬁc demographics and cancer incidence. Hence, further
reﬁnement accounting for the population structure, epidemiology
and radiotherapy utilization, as well as for evolving technology
and treatment strategies, seemed essential. This was the rationale
for developing a model, described in the second part of the QUARTS
analysis [25], where the best available evidence on radiotherapy
indications in 23 main cancer types was combined with epidemio-
logical data from all 25 EU countries at that time and with pub-
lished benchmarks for accelerator throughput. From this analysis,
it became clear that the large variation in crude cancer incidence
observed within the analyzed EU countries indeed translates into
a similarly large variation in the estimated number of required lin-
ear accelerators per million inhabitants (between 4.0 and 8.1. li-
nacs/million), hovering around a European average of 5.9. These
data were subsequently compared with the national guidelines
and the existent availability of infrastructure, revealing major
inequalities among the analyzed EU countries and large discrepan-
cies between optimal and available infrastructure in some. The
largest gap between the actual situation and the calculated
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United Kingdom, supporting the expansion of radiotherapy capac-
ity in these countries, as it may have implications for radiotherapy
utilization and practice, as described earlier [22,24]. On the other
end of the spectrum, Sweden, France and Belgium were countries
where the availability of megavoltage units exceeded 90% of the
calculated need.The ESTRO HERO project
Although data as presented in QUARTS are indispensible to
guide actions toward optimal radiotherapy provision within the
more global context of national health care plans, they clearly only
represent a snapshot in time. Not only do they need to be regularly
corrected for the changing cancer incidence and demographics (not
in the least in relation to the aging of our Western population),
they should equally take the evolving evidence on radiotherapy
indications and utilization into account, in view of correctly fore-
casting future radiotherapy resource needs. Moreover, the radio-
therapy community – and more speciﬁcally the European Society
for Radiotherapy and Oncology (ESTRO) – has become more than
conscious of the ever-increasing necessity to come up with objec-
tive data to endorse the crucial role and position of radiation oncol-
ogy within the rapidly changing global oncology landscape. In an
era of ever expanding health care costs, proven safety and effec-
tiveness is not sufﬁcient anymore to obtain funding, objective data
about cost and cost-effectiveness are nowadays additionally
requested.
It is in this context that the ESTRO is launching the HERO-pro-
ject (Health Economics in Radiation Oncology), with the overall
aim to develop a knowledge base and a model for health economic
evaluation of radiation treatments at the European level. To
accomplish these objectives, the HERO project will address ﬁve dif-
ferent dimensions.
The need for radiotherapy will be assessed by deﬁning the opti-
mum radiotherapy utilization in Europe derived from cancer inci-
dence and evidence-based guidelines. Resources required to
deliver this deﬁned optimum level of care will be determined. Pro-
vision and accessibility will be addressed by surveying national rec-
ommendations on infrastructure and stafﬁng levels, compared
with the available resources in European countries and the esti-
mated need, using the QUARTS methodology. In addition, the ac-
tual radiotherapy treatment mix delivered within the different
countries will be documented.
With the former data on radiotherapy population and resources
at hand, a cost-accounting program for radiotherapy will be devel-
oped at the European level, using Activity-Based Costing method-
ology. The generated cost data will subsequently form the basis
of economic evaluations, using decision analytic models.
As a ﬁnal step in the HERO project, the identiﬁed key ﬁgures and
cost(-effectiveness) data will be used for proﬁling radiotherapy in
the global cancer management context and to help countries prior-
itize the most cost-effective approaches. It should moreover help in
the deﬁnition of optimal reimbursement strategies in order to
tackle the potential discrepancy between the evidence-based need
and the radiotherapy resources available in different countries.
It is only by investing in this kind of research that the radiother-
apy community can demonstrate that radiotherapy truly delivers
value for money, even in the context of innovative, more resource
demanding, technologies. This will in term hopefully facilitate the
interaction with governmental and insurance parties, make us
equal partners in health care management, decision-making and
budgeting and as a ﬁnal consequence allow us to deliver high-qual-
ity radiotherapy to each individual patient. By highlighting health
economic aspects and potential inadequacies across Europe, wehope to strengthen the position of radiation oncology and hence,
in a more global sense, lead to improved cancer care.Conﬂict of interest
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